Are soluble APP-α and APP-β in CSF valuable for earlier diagnosis of dementia disorders?

Written by Wataru Araki (National Center of Neurology and Psychiatry, Japan) and Yumiko M. Araki (National Center of Neurology and Psychiatry and Juntendo University, both Japan)

sAPPα and sAPPβ as potential biomarkers of dementia disorders Alzheimer’s disease (AD), characterized by the cerebral accumulation of the well-known pathological hallmark proteins, amyloid β-protein (Aβ) and phosphorylated tau (p-tau) protein, is the most prevalent dementia disorder. Recent studies have revealed that Aβ deposition gradually progresses during a long asymptomatic period that precedes the onset of mild cognitive impairment (MCI) due to AD (MCI-AD); this phase is now called preclinical AD [1]. Thus, the brain pathology evidently develops at the MCI-AD stage. Taking into account such characteristic features of disease progression, it becomes increasingly critical to accurately diagnose dementia disorders...

To view the full article, please register now for access

It's completely free